ES2527664T3 - Tratamiento de la cistitis intersticial con una dosis alta de sulfato de condroitina - Google Patents

Tratamiento de la cistitis intersticial con una dosis alta de sulfato de condroitina Download PDF

Info

Publication number
ES2527664T3
ES2527664T3 ES04711966.4T ES04711966T ES2527664T3 ES 2527664 T3 ES2527664 T3 ES 2527664T3 ES 04711966 T ES04711966 T ES 04711966T ES 2527664 T3 ES2527664 T3 ES 2527664T3
Authority
ES
Spain
Prior art keywords
treatment
chondroitin sulfate
interstitial cystitis
high dose
insufficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04711966.4T
Other languages
English (en)
Inventor
Peter R. Riehl
Sungtack Samuel Hahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TRIBUTE PHARMACEUTICALS CANADA Inc
TRIBUTE PHARMACEUTICALS CANADA Inc
Original Assignee
TRIBUTE PHARMACEUTICALS CANADA Inc
TRIBUTE PHARMACEUTICALS CANADA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32850064&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2527664(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by TRIBUTE PHARMACEUTICALS CANADA Inc, TRIBUTE PHARMACEUTICALS CANADA Inc filed Critical TRIBUTE PHARMACEUTICALS CANADA Inc
Application granted granted Critical
Publication of ES2527664T3 publication Critical patent/ES2527664T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica para utilizar en el tratamiento de un paciente humano que padece cistitis intersticial o afecciones vesicales y/o de las vías urinarias relacionadas, mediante la administración por instilación en la vejiga del paciente, donde las afecciones relacionadas son formas de cistitis con insuficiencia de GAG o insuficiencia de GAG que acompaña a una infección crónica de las vías urinarias, y donde la composición consiste en una dosis unitaria de sulfato de condroitina en una cantidad de al menos 400 mg y un vehículo acuoso.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
ES04711966.4T 2003-02-19 2004-02-18 Tratamiento de la cistitis intersticial con una dosis alta de sulfato de condroitina Expired - Lifetime ES2527664T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US367970 2003-02-19
US10/367,970 US20040161476A1 (en) 2003-02-19 2003-02-19 Cystitis treatment with high dose chondroitin sulfate
PCT/CA2004/000244 WO2004073584A2 (en) 2003-02-19 2004-02-18 Cystitis treatment with high dose chondroitin sulfate

Publications (1)

Publication Number Publication Date
ES2527664T3 true ES2527664T3 (es) 2015-01-28

Family

ID=32850064

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04711966.4T Expired - Lifetime ES2527664T3 (es) 2003-02-19 2004-02-18 Tratamiento de la cistitis intersticial con una dosis alta de sulfato de condroitina

Country Status (15)

Country Link
US (5) US20040161476A1 (es)
EP (2) EP2857024A1 (es)
JP (1) JP4778888B2 (es)
CN (1) CN1758920B (es)
AU (1) AU2004212650B2 (es)
CA (1) CA2515512C (es)
CY (1) CY1116069T1 (es)
DE (1) DE14189577T9 (es)
DK (1) DK1603578T3 (es)
ES (1) ES2527664T3 (es)
HK (2) HK1085136A1 (es)
IL (2) IL170309A (es)
PT (1) PT1603578E (es)
SI (1) SI1603578T1 (es)
WO (1) WO2004073584A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate
US20070173479A1 (en) * 2003-12-10 2007-07-26 Keryx Biopharmaceuticals, Inc. Methods Using Sulodexide for the Treatment of Bladder Disease
PT1708722E (pt) 2004-01-28 2014-09-12 Univ California Nova terapia interstciial para o alívio imediato dos sintomas e terapia crónica na cistite intersticial
ITMI20061030A1 (it) * 2006-05-26 2007-11-27 Altergon Sa Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica
US20090023637A1 (en) * 2006-08-30 2009-01-22 Parsons C Lowell Methods for detecting and treating interstitial cystitis
DE102006060953A1 (de) * 2006-12-12 2008-08-07 Farco-Pharma Gmbh Pharmazeutische Zubereitung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes
WO2008144485A2 (en) * 2007-05-18 2008-11-27 University Of Maryland, Baltimore Inhibition of palmitoyl acyl transferase expression and/or activity for the regulation of antiproliferative factor activity
US9849086B2 (en) * 2012-03-19 2017-12-26 Nanologix Research, Inc. Method and composition for treating cystitis
CN107108761B (zh) * 2015-01-09 2020-06-30 生化学工业株式会社 硫酸软骨素衍生物和膀胱疾病处置剂
EP3512561A4 (en) 2016-09-16 2020-10-07 Glycologix, LLC SULFATED GLYCOSAMINOGLYCAN BIOMATERIALS AS PROTEOGLYCAN MIMETICS
DE202017103288U1 (de) 2017-05-12 2018-05-16 Farco-Pharma Gmbh Zusammensetzung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes in Form einer hochdosierten Wirkstoffkombination
EP3400950B1 (de) 2017-05-12 2019-11-13 Farco-Pharma GmbH Blaseninstillationszusammensetzung enthaltend chondoitinsulfat (20 mg/ml), hyaluronsäure (16 mg/ml) und phosphatpuffer (ph 6,1 bis 7,9) mit erhöhter lagerstabiliät zur behandlung von cystitis
DE202017103289U1 (de) 2017-05-12 2018-05-16 Farco-Pharma Gmbh Zusammensetzung für die Behandlung entzündlicher Erkrankungen des Urogenitaltraktes in Form einer Wirkstoffkombination
ES2775673T3 (es) * 2017-05-12 2020-07-27 Farco Gmbh Composición para el tratamiento de enfermedades inflamatorias del tracto urogenital que contiene sulfato de condonita (4,5 mg/ml), ácido hialurónico (16 mg/ml) y tampón de fosfato (pH 6,1 a 7,9) con mayor estabilidad de almacenamiento para tratar la cistitis
EP3415163B1 (de) 2017-06-13 2023-02-22 Farco-Pharma GmbH Zusammensetzung mit lokalanästhetischer wirkung und deren verwendung
DE202017104675U1 (de) 2017-06-13 2018-06-14 Farco-Pharma Gmbh Zusammensetzung mit lokalanästhetischer Wirkung und deren Verwendung
WO2022246405A1 (en) * 2021-05-18 2022-11-24 Karuna Therapeutics, Inc. Methods for treating central nervous system disorders with muscarinic receptor activation and antipsychotics

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971955A (en) * 1981-03-02 1990-11-20 Soll David B Protection of human and animal cells during surgical trauma
FR2535324A1 (fr) * 1982-10-27 1984-05-04 Choay Sa Station perfectionnee pour l'epuration d'eaux usees
CA1187798A (en) 1982-03-24 1985-05-28 David B. Soll Protection of cells
AU555747B2 (en) 1983-08-09 1986-10-09 Cilco Inc. Chondroitin sulfate and sodium hyaluronate composition
US4886786A (en) * 1985-08-01 1989-12-12 Lindstrom Richard L Additive for irrigation solution or surgical solution
EP0240098A3 (en) * 1986-04-04 1989-05-10 Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo Oligo and polysaccharides for the treatment of diseases caused by retroviruses
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
US5541166A (en) * 1987-01-23 1996-07-30 The Australian National University Sulphated polysaccharides having anti-metastatic and/or anti-inflammatory activity
US5037810A (en) * 1987-03-17 1991-08-06 Saliba Jr Michael J Medical application for heparin and related molecules
IT1217458B (it) * 1988-05-02 1990-03-22 Crinos Ind Farmacoriologica S Sulfoamino derivati di condroitin solfati,del dermatan solfato e dell' acido ialuronico e loro proprieta' farmacologiche
WO1991006303A1 (en) 1989-10-27 1991-05-16 Case Western Reserve University Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
CA2020199C (en) 1990-06-29 2002-08-20 Daniel Bar-Shalom Uses of sulphated sugars
DE4021066A1 (de) 1990-07-03 1992-01-09 Hoechst Ag Langzeitprophylaxe gegen erkrankungen, die durch viren oder durch unkonventionelle viren verursacht werden
CA2060223C (en) 1991-02-12 1999-07-20 Clarence C. Lee Injectable medical lubricating fluid composition and method of use
IT1245907B (it) 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
IL102758A (en) 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
EP0571597A4 (en) 1991-11-15 1994-06-01 Arthro Res & Dev Corp Method for treatment of acute and chronic painful arthropathic conditions in human and other mammals
EP0636631A1 (en) * 1992-04-17 1995-02-01 Seikagaku Corporation Platinum complex and antineoplastic agent
WO1994000135A1 (en) 1992-06-30 1994-01-06 Shapiro Howard K Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
IT1264530B (it) * 1992-07-31 1996-10-02 Crinos Industria Farmaco Impiego dei polisaccaridi nelle neuropatie atrofico degenerative
US6492349B1 (en) * 1993-03-31 2002-12-10 Nutramax Laboratories, Inc. Aminosugar and glycosaminoglycan composition for the treatment and repair of connective tissue
NZ260933A (en) 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
CA2130295A1 (en) 1993-08-26 1995-02-27 Richard A. Berg Ionically crosslinked glycosaminoglycan gels for soft tissue augmentation and drug delivery
AU698881B2 (en) 1994-05-11 1998-11-12 Howard K. Shapiro Compositions for treatment of chronic inflammatory diseases
IN181358B (es) 1995-02-14 1998-05-30 Bioniche Inc
AUPN261895A0 (en) * 1995-04-28 1995-05-18 Australian National University, The Preparation and use of sulfated oligosaccharides
CN1196734A (zh) * 1995-09-19 1998-10-21 生化学工业株式会社 消炎药
CA2217134A1 (en) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Sustained release formulation
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
US20030232100A1 (en) * 1998-04-08 2003-12-18 Theoharides Theoharis C. Compositions for treatment of diseases arising from secretion of mast cell biochemicals
CA2269260C (en) 1999-04-16 2002-12-31 Stellar International Inc. Treatment of cystitis with chondroitin sulfate
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
JP2001213784A (ja) * 2000-02-03 2001-08-07 Teisan Seiyaku Kk 乳牛の***炎治療剤
EP1311276A4 (en) * 2000-07-31 2007-09-12 Dermal Res Lab Inc METHODS FOR THE PREVENTION OR TREATMENT OF DISEASES AND CONDITIONS USING COMPLEX CARBOHYDRATES
US7485629B2 (en) * 2002-10-16 2009-02-03 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treatment of joint damage
US6979679B2 (en) * 2002-10-16 2005-12-27 Marcum Frank D Composition and method for treatment and prevention of traumatic synovitis and damage to articular cartilage
US7504387B2 (en) * 2002-10-16 2009-03-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan composition and method for treatment and prevention of interstitial cystitis
US20040161476A1 (en) 2003-02-19 2004-08-19 Hahn Sungtack Samuel Cystitis treatment with high dose chondroitin sulfate

Also Published As

Publication number Publication date
IL170309A (en) 2015-11-30
EP1603578B1 (en) 2014-10-29
US8084441B2 (en) 2011-12-27
US20100292182A1 (en) 2010-11-18
CA2515512A1 (en) 2004-09-02
SI1603578T1 (sl) 2015-04-30
AU2004212650B2 (en) 2009-07-23
HK1209037A1 (en) 2016-03-24
WO2004073584A3 (en) 2005-01-27
IL238811A0 (en) 2015-06-30
US8334276B2 (en) 2012-12-18
DE14189577T9 (de) 2020-12-10
CN1758920B (zh) 2010-05-26
US20130143839A1 (en) 2013-06-06
US8778908B2 (en) 2014-07-15
WO2004073584A2 (en) 2004-09-02
CY1116069T1 (el) 2017-02-08
EP1603578A2 (en) 2005-12-14
DK1603578T3 (en) 2015-01-19
HK1085136A1 (en) 2006-08-18
JP2006517928A (ja) 2006-08-03
US20120058969A1 (en) 2012-03-08
JP4778888B2 (ja) 2011-09-21
AU2004212650A1 (en) 2004-09-02
US20060194757A1 (en) 2006-08-31
CA2515512C (en) 2012-07-10
US20040161476A1 (en) 2004-08-19
PT1603578E (pt) 2014-12-11
DE14189577T1 (de) 2019-10-17
US7772210B2 (en) 2010-08-10
CN1758920A (zh) 2006-04-12
IL238811A (en) 2017-03-30
EP2857024A1 (en) 2015-04-08

Similar Documents

Publication Publication Date Title
ES2527664T3 (es) Tratamiento de la cistitis intersticial con una dosis alta de sulfato de condroitina
ES2526463T3 (es) Exendina para el tratamiento de la diabetes y la reducción del peso corporal
De Waele et al. Epidemiology of augmented renal clearance in mixed ICU patients
ES2611483T3 (es) Agente terapéutico para enfermedad inflamatoria intestinal
Martins et al. Treatment of denture stomatitis: literature review
RU2011115406A (ru) Новые пиримидиновые производные и их применение в терапии, а также применение пиримидиновых производных в изготовлении лекарственного средства для предупреждения и/или лечения болезни альцгеймера
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
EA200802204A1 (ru) Применение ингибиторов dpp iv
CL2008002852A1 (es) Compuestos derivados de 7-fluoro-5-metil-2-(fenilamino)-6,7,8,9-tetrahidro-5h-pirimido[4,5-b][1,4]diazepin-6(7h)-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de canceer, inflamacion, alopecia, enfermedades autoinmune, cardiovasculares, infecciosas, nefrologicas, neurodfegenerativas, cutaneas y oseas.
ES2525931T3 (es) Composiciones y métodos para prevenir o tratar enfermedad inflamatoria intestinal
PT1163904E (pt) Composicao para a prevencao de doencas do musculo liso, compreendendo ascorbato, arginina e magnesio
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
ES2521674T3 (es) Métodos de tratamiento de hiperuricemia y estados patológicos asociados
ECSP077843A (es) Tratamiento o prevención del prurito
ES2491565T3 (es) Agente de transfección
AR048806A1 (es) Uso de cariofilenos en la elaboracion de medicamentos y tratamiento de afecciones corporales de inflamacion y dolor inflamatorio
AR052015A1 (es) Agente para la profilaxis o tratamiento del sindrome metabolico
CN207679425U (zh) 新型***镜
DE602004017164D1 (de) Albuminkonjugate, die eine Glucuron-Verknüpfung enthalten
Martins et al. Tratamento da estomatite protética: revisão de literatura
PL417983A1 (pl) Zastosowanie medyczne 5,7-dihydroksy-3-(4-hydroksyfenylo)-4H-1-benzopiran-4-onu w terapii choroby Huntingtona oraz farmaceutycznie akceptowalna postać leku
ES2461564T3 (es) Uso de histonas para fines terapéuticos
RU2005130403A (ru) Средство для лечения или предотвращения заболеваний, связанных с пониженным метаболизмом костной ткани
CN108926323A (zh) 一种带混合涂层螺纹软镜鞘的分体式膀胱硬镜
ES2534419T3 (es) Utilización de anticuerpos contra un antígeno asociado con un tumor